CFH and complement 3 glomerulopathy: Preclinical studies have recently tested the potential therapeutic effect of C3d-targeted CR11–10 and FH1–5 in C3 glomerulopathies (C3G) by studying their tissue localization and complement inhibition effectiveness in CfH knockout mice (CfH-/-) (9, 10).